Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06043427 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Jun 30, 2026 → Dec 31, 2026
See other at-risk trials from Canadian Cancer Trials Group

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jun 30, 2026 to Dec 31, 2026
    • Study completion pushed from Dec 31, 2026 to Jul 31, 2027
    v20
  2. Site details revised at 1 of 18 sitesv19
  3. Site details revised at 1 of 18 sitesv18
  4. Primary completion date: Dec 31, 2025 to Jun 30, 2026
    • Study completion date: Jun 30, 2026 to Dec 31, 2026
    v17
  5. Site details revised at 1 of 18 sitesv16
Show 14 earlier versionsHide 14 earlier versions
  1. Study sites: 17 to 18v15
  2. Study sites: 16 to 17v14
  3. Site details revised at 1 of 16 sitesv13
  4. Study sites: 14 to 16v12
  5. Study sites: 15 to 14v11
  6. Site contacts updated at 1 of 15 sitesv10
  7. Study sites revised (15)v9
  8. Study sites: 10 to 15v8
  9. Study sites: 8 to 10v7
  10. Study sites: 4 to 8v6
  11. Study sites: 1 to 4v5
  12. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 31, 2024 to Apr 16, 2024
    v4
  13. Start date: Jan 15, 2024 to Mar 31, 2024v3
  14. Start date: Oct 16, 2023 to Jan 15, 2024v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is being done to answer the following question: Can the chance of gastroesophageal cancer growing or spreading be lowered by adding a drug called zanidatamab to the usual combination of drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as care most people get for gastroesophageal cancer
Trial Details
NCT Number NCT06043427
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Jazz Pharmaceuticals
Conditions
(from sponsor)		 Gastroesophageal Adenocarcinoma
Enrollment 168 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov